Clinical and Imaging Features of Tepotinib-Induced Interstitial Lung Disease in the Post-Marketing Setting in Japan.

Kato T, Baba T, Endo M, Endo S, Horii E, Kusumoto M

DOI: 10.1111/cas.70471
Published: 2026 Jul 14
Container: Cancer science
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1111/cas.70471,
  title = {Clinical and Imaging Features of Tepotinib-Induced Interstitial Lung Disease in the Post-Marketing Setting in Japan.},
  author = {Kato T and Baba T and Endo M and Endo S and Horii E and Kusumoto M},
  year = {2026},
  journal = {Cancer science},
  doi = {10.1111/cas.70471},
  url = {https://doi.org/10.1111/cas.70471}
}

RIS

TY  - JOUR
TI  - Clinical and Imaging Features of Tepotinib-Induced Interstitial Lung Disease in the Post-Marketing Setting in Japan.
AU  - Kato T
AU  - Baba T
AU  - Endo M
AU  - Endo S
AU  - Horii E
AU  - Kusumoto M
PY  - 2026
JO  - Cancer science
DO  - 10.1111/cas.70471
UR  - https://doi.org/10.1111/cas.70471
ER  -

APA

T, K., T, B., M, E., S, E., E, H., & M, K. (2026). Clinical and Imaging Features of Tepotinib-Induced Interstitial Lung Disease in the Post-Marketing Setting in Japan.. Cancer science. https://doi.org/10.1111/cas.70471

Source records

pubmed · retrieved 2026-09-26T23:55:53.617Z